Cromos Pharma, where the patients are

R&D Trends

DuchenneConnect to join new national clinical research network

Monday, February 24, 2014 12:00 PM

DuchenneConnect, a program of Parent Project Muscular Dystrophy (PPMD), has been awarded $970,000 by the Patient-Centered Outcomes Research Institute (PCORI) to take part in developing a health data network. DuchenneConnect will be part of PCORnet: the National Patient-Centered Clinical Research Network. The DuchenneConnect network is one of 29 networks that were approved for PCORnet. The formation of the new national PCORnet resource aims to boost the efficiency of health research.

More... »

CRF Health eCOA webinar series

AstraZeneca scientists to work alongside researchers at Cancer Research UK Cambridge

Monday, February 24, 2014 11:38 AM

AstraZeneca has entered into a collaboration with the Cancer Research U.K. (CRUK) Cambridge Institute to temporarily locate up to 60 AstraZeneca scientists in the Institute.

More... »

Report: Schizophrenia market to gain slight boost by 2022, unmet needs remain

Monday, February 24, 2014 11:21 AM

The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from research and consulting firm GlobalData.

More... »

CURx Pharmaceuticals, Gilead Sciences form license agreement

Monday, February 24, 2014 11:00 AM

CURx Pharmaceuticals, a San Diego-based developer of late-stage therapeutics with high medical need, has entered into a global license agreement with Gilead Sciences for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for phase III clinical trials, having successfully completed a phase II trial in CF patients.

More... »

Report: Latin American diabetes therapeutics market to transform

Wednesday, February 19, 2014 01:27 PM

The Latin American diabetes therapeutics market will experience major changes within the next three years due to the launch of innovative drugs that include three long-acting insulins and four non-insulin treatments. Nevertheless, pharmaceutical companies should continue their research to develop treatments that can restore beta-cell function and thereby postpone or prevent disease progression—areas that even newer therapies do not address.

More... »

Report: U.S. biopharma companies currently developing 182 diabetes treatments

Wednesday, February 19, 2014 01:24 PM

America’s biopharmaceutical research companies currently are developing 182 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development—all either in clinical trials or under review by the FDA—include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

Novartis acquires CoStim

Wednesday, February 19, 2014 01:20 PM

Novartis is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

More... »

Report: Venture capital in life sciences sector trailing other industries

Wednesday, February 19, 2014 01:14 PM

Venture capital funding for the life sciences sector, which includes biotechnology and medical devices, declined in 2013 by 1% in dollars invested and 3% in number of deals, compared to 2012, according to a new PwC U.S. report, Medtech Slowdown, which includes data from the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters

More... »

Soligenix recieves $300,000 NIAID SBIR grant award for Melioidosis

Friday, February 14, 2014 01:46 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.

More... »

Medimmune, UC San Francisco collaborate

Friday, February 14, 2014 01:40 PM

MedImmune, the global biologics R&D arm of AstraZeneca, has entered a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF).  The collaboration will focus on CTSI's Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research beyond the bench and into product development.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs